250 related articles for article (PubMed ID: 21576640)
1. Success story of targeted therapy in chronic myeloid leukemia: a population-based study of patients diagnosed in Sweden from 1973 to 2008.
Björkholm M; Ohm L; Eloranta S; Derolf A; Hultcrantz M; Sjöberg J; Andersson T; Höglund M; Richter J; Landgren O; Kristinsson SY; Dickman PW
J Clin Oncol; 2011 Jun; 29(18):2514-20. PubMed ID: 21576640
[TBL] [Abstract][Full Text] [Related]
2. Frequency of BCR-ABL gene mutations in Polish patients with chronic myeloid leukemia treated with imatinib: a final report of the MAPTEST study.
Lewandowski K; Warzocha K; Hellmann A; Skotnicki A; Prejzner W; Foryciarz K; Sacha T; Gniot M; Majewski M; Solarska I; Nowak G; Wasag B; Kobelski M; Scibiorski C; Siemiatkowski M; Lewandowska M; Komarnicki M
Pol Arch Med Wewn; 2009 Dec; 119(12):789-94. PubMed ID: 20010464
[TBL] [Abstract][Full Text] [Related]
3. Targeted chronic myeloid leukemia therapy: Seeking a cure.
Fausel C
Am J Health Syst Pharm; 2007 Dec; 64(24 Suppl 15):S9-15. PubMed ID: 18056932
[TBL] [Abstract][Full Text] [Related]
4. First-line therapy for CML: nilotinib comes of age.
Davies J
Lancet Oncol; 2011 Sep; 12(9):826-7. PubMed ID: 21856227
[No Abstract] [Full Text] [Related]
5. ApoptomiRs expression modulated by BCR-ABL is linked to CML progression and imatinib resistance.
Ferreira AF; Moura LG; Tojal I; Ambrósio L; Pinto-Simões B; Hamerschlak N; Calin GA; Ivan C; Covas DT; Kashima S; Castro FA
Blood Cells Mol Dis; 2014; 53(1-2):47-55. PubMed ID: 24629639
[TBL] [Abstract][Full Text] [Related]
6. Excellent outcomes of children with CML treated with imatinib mesylate compared to that in pre-imatinib era.
Muramatsu H; Takahashi Y; Sakaguchi H; Shimada A; Nishio N; Hama A; Doisaki S; Yagasaki H; Matsumoto K; Kato K; Kojima S
Int J Hematol; 2011 Feb; 93(2):186-191. PubMed ID: 21234820
[TBL] [Abstract][Full Text] [Related]
7. [Tyrosine kinase inhibitors for the treatment of CML].
Heim D
Ther Umsch; 2006 Apr; 63(4):249-54. PubMed ID: 16689455
[TBL] [Abstract][Full Text] [Related]
8. [Tyrosine kinase inhibitors in the therapy of chronic myeloid leukaemia].
Grzybowska-Izydorczyk O; Góra-Tybor J; Robak T
Postepy Hig Med Dosw (Online); 2006; 60():490-7. PubMed ID: 17013368
[TBL] [Abstract][Full Text] [Related]
9. The role of allogeneic stem cell transplantation for CML in the tyrosine kinase inhibitor era.
Cutler C; Antin JH
Curr Hematol Malig Rep; 2006 Sep; 1(3):160-7. PubMed ID: 20425347
[TBL] [Abstract][Full Text] [Related]
10. Double minutes containing amplified bcr-abl fusion gene in a case of chronic myeloid leukemia treated by imatinib.
Morel F; Bris MJ; Herry A; Calvez GL; Marion V; Abgrall JF; Berthou C; Braekeleer MD
Eur J Haematol; 2003 Apr; 70(4):235-9. PubMed ID: 12656747
[TBL] [Abstract][Full Text] [Related]
11. PD166326, a novel tyrosine kinase inhibitor, has greater antileukemic activity than imatinib mesylate in a murine model of chronic myeloid leukemia.
Wolff NC; Veach DR; Tong WP; Bornmann WG; Clarkson B; Ilaria RL
Blood; 2005 May; 105(10):3995-4003. PubMed ID: 15657179
[TBL] [Abstract][Full Text] [Related]
12. Hematological and molecular response evaluation of CML patients on imatinib.
Gupta A; Prasad K
J Assoc Physicians India; 2007 Feb; 55():109-13. PubMed ID: 17571739
[TBL] [Abstract][Full Text] [Related]
13. Impact of prior imatinib mesylate on the outcome of hematopoietic cell transplantation for chronic myeloid leukemia.
Lee SJ; Kukreja M; Wang T; Giralt SA; Szer J; Arora M; Woolfrey AE; Cervantes F; Champlin RE; Gale RP; Halter J; Keating A; Marks DI; McCarthy PL; Olavarria E; Stadtmauer EA; Abecasis M; Gupta V; Khoury HJ; George B; Hale GA; Liesveld JL; Rizzieri DA; Antin JH; Bolwell BJ; Carabasi MH; Copelan E; Ilhan O; Litzow MR; Schouten HC; Zander AR; Horowitz MM; Maziarz RT
Blood; 2008 Oct; 112(8):3500-7. PubMed ID: 18664621
[TBL] [Abstract][Full Text] [Related]
14. Major molecular response in CML patients treated with tyrosine kinase inhibitors: the paradigm for monitoring targeted cancer therapy.
Press RD
Oncologist; 2010; 15(7):744-9. PubMed ID: 20566700
[TBL] [Abstract][Full Text] [Related]
15. Polo-like kinase 1 (Plk1) as a novel drug target in chronic myeloid leukemia: overriding imatinib resistance with the Plk1 inhibitor BI 2536.
Gleixner KV; Ferenc V; Peter B; Gruze A; Meyer RA; Hadzijusufovic E; Cerny-Reiterer S; Mayerhofer M; Pickl WF; Sillaber C; Valent P
Cancer Res; 2010 Feb; 70(4):1513-23. PubMed ID: 20145140
[TBL] [Abstract][Full Text] [Related]
16. Improved survival in chronic myeloid leukemia since the introduction of imatinib therapy: a single-institution historical experience.
Kantarjian H; O'Brien S; Jabbour E; Garcia-Manero G; Quintas-Cardama A; Shan J; Rios MB; Ravandi F; Faderl S; Kadia T; Borthakur G; Huang X; Champlin R; Talpaz M; Cortes J
Blood; 2012 Mar; 119(9):1981-7. PubMed ID: 22228624
[TBL] [Abstract][Full Text] [Related]
17. Status of leptin in MBCR-ABL p210 positive chronic myeloid leukemia patients before and after imatinib therapy: a conflicting scenario.
Bansal P; Ghalaut VS; Sharma TK; Ghalaut PS; Dokwal S; Ghalaut R; Kulshrestha M; Dahiya K
Clin Lab; 2014; 60(11):1845-52. PubMed ID: 25648025
[TBL] [Abstract][Full Text] [Related]
18. Five-year follow-up of patients treated with imatinib mesylate for chronic myeloid leukaemia in Trinidad and Tobago.
Charles KS; Ramon L; Leelah N; Oluwabusi TA; Seemungal T
West Indian Med J; 2011 Jun; 60(3):298-302. PubMed ID: 22224342
[TBL] [Abstract][Full Text] [Related]
19. Imatinib mesylate (STI571) therapy for Philadelphia chromosome-positive chronic myelogenous leukemia in blast phase.
Kantarjian HM; Cortes J; O'Brien S; Giles FJ; Albitar M; Rios MB; Shan J; Faderl S; Garcia-Manero G; Thomas DA; Resta D; Talpaz M
Blood; 2002 May; 99(10):3547-53. PubMed ID: 11986206
[TBL] [Abstract][Full Text] [Related]
20. Molecular monitoring of response to imatinib (Glivec) in chronic myeloid leukemia patients: experience at a tertiary care hospital in Saudi Arabia.
Khalil SH; Abu-Amero KK; Al Mohareb F; Chaudhri NA
Genet Test Mol Biomarkers; 2010 Feb; 14(1):67-74. PubMed ID: 19943786
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]